Baxter's Turnaround Gains Momentum: Tariff Refund and Execution Lift Guidance, but Novum Casts a Long Shadow
Tariff refund and a rare top-line beat
Baxter's second quarter of 2026 delivered a welcome upside surprise. Organic sales grew 5% year-over-year, right at the top of management's initial expectations, and the quarter included an IEEPA tariff refund of $75 million that was not contemplated in original guidance. As Andrew Hider noted, “results reflect a tariff refund that was not contemplated in our original guidance” — Andrew Hider, CEO · 2026-07-30 and the company promptly raised full-year organic sales growth to 2%–3% (from roughly flat) and adjusted EPS to $1.95–$2.15. The stock has responded with a +53.6% rally over the past 90 days, reaching a peak of $28.35 in early August.
The tariff refund is a one-time benefit, but it reinforces the company's liquidity and helps explain the confidence behind the deleveraging path. CFO Anita Zielinski emphasized that free cash flow was positive for the second consecutive quarter, and management reiterated its target of approximately 3x net leverage by year-end. The refund also allowed the company to absorb some of the known mechanical headwinds—higher cost inventory produced at the end of 2025 and an unfavorable prior-year comparison—that had pressured margins earlier in the year.
Segment strength and margin pressure
Growth was broad-based, with every division contributing. In Medical Products & Therapies (MPT), Drug Compounding again stood out, growing double digits and helping offset softness in injectables and premix products. Advanced Surgery also delivered a strong 12% increase, while Healthcare Systems & Technologies (HST) grew 4% on robust patient support systems demand. The company is now reporting its combined Infusion Therapies & Platforms (ITP) division, reflecting the integration of Pharmaceuticals with the former ITT business—a move that should improve coordination and execution.
However, margins remain under pressure. Adjusted gross margins fell 210 basis points to 38.6%, driven by higher manufacturing costs and the unfavorable roll-through of higher-cost inventory. As Kevin Moran explained, “that is what the new EPS guidance reflects is the inclusion of that refund in Q2.” — Kevin Moran, Vice President, Investor Relations · 2026-07-30 Excluding the refund, the underlying earnings would have been slightly below prior-year levels. Management expects margins to improve in the second half as volumes increase and the cost structure actions from earlier in the year begin to flow through.
The Novum overhang
The lingering issue remains the Novum IQ LVP. The voluntary shipment and installation hold, in place since late 2025, continues to weigh on the pump portfolio. Yet the company is making incremental progress on corrective actions and remains confident in the overall platform. This is a recurring theme from prior calls; in April 2026, management said, “we haven't explicitly quantified what the potential risk is for returns... but we think it's prudent to assume that this potential could happen.” — Kevin Moran, Vice President, Investor Relations · 2026-04-30 While the company now expresses growing confidence, the hold is still expected to last through the year, and the risk of customer returns persists.
Despite these challenges, the broader turnaround story is gaining credibility. Management's emphasis on Baxter GPS—the continuous improvement program—has led to over 400 improvement events year-to-date, and the company is positioning itself to return to sustainable growth. The prior guidance had already signaled modest 2027 expansion; as Andrew Hider said in February, “we would expect to grow earnings modestly as well.” — Andrew Hider, Chief Executive Officer · 2026-04-30 The second quarter's performance supports that narrative, though the tariff refund is not a recurring revenue stream.
We are now in a stronger position to deliver on the financial goals we set at the start of the year. I am pleased with the progress we are making, but I'm far from satisfied.
Leverage, cash flow, and the path forward
Free cash flow generation has been a bright spot, with year-to-date free cash flow of $257 million. This supports the balance sheet strengthening that management has prioritized. The company's gross margin, while down year-over-year, is expected to improve sequentially in the second half as the higher-cost inventory rolls through. Gross margins remain well below historical levels, and margin expansion is a key watch item.
Looking ahead, the key drivers are clear: continued organic growth, margin improvement from volume and cost actions, and disciplined capital allocation. The tariff refund provides a one-time boost, but the underlying operational execution is what will sustain the turnaround. With the Novum situation slowly resolving and new product launches like the Connex 360 monitoring platform and the Dynamo smart stretcher gaining traction, Baxter is positioning itself for a more predictable performance profile as it heads into 2027.